{
  "docId": "019de071-fee7-744f-89ad-50de02e7ef2c",
  "docSlug": "b5a336d0fe4b7b554c90c4664e01c224",
  "documentTitle": "Comera | SPAC Presentation Deck | 33 slides",
  "authorId": "comera",
  "authorName": "Comera Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 33,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Focuses on toxicity results from animal studies (Sprague Dawley rats) comparing IV and SQ administration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-fee7-744f-89ad-50de02e7ef2c/19",
  "deckHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c",
  "deckJsonHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c.json",
  "deckAnchorHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.048,
        "y": 0.845
      },
      "kind": "callout",
      "text": "Based on data collected-to-date, administered subcutaneously, caffeine-containing mAb formulations have not demonstrated evidence of local or systemic toxicity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8e1988e-b4bb-414f-a29d-aff14c49aa00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.048,
        "y": 0.29
      },
      "kind": "list",
      "text": "Animal studies conducted by the Company to assess SQore formulation viability to deliver mAbs subcutaneously. Study #1: no toxicity from caffeine formulation on the test animals. Study #2: no evidence of local or systemic toxicity reported to-date.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "034c29ab-75aa-4024-8082-53690657092b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.048,
        "y": 0.595
      },
      "kind": "table",
      "text": "Study #2 Goals: Comparison of IV and SQ-administered formulations; Determine PK profile and bioavailability; Testing a control formulation vs. a caffeine containing mAb formulation; Observe the animals (SD rats) for any signs of health effects",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "974cb959-b945-422a-b0b6-d6782c97350a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.94,
        "x": 0.048,
        "y": 0.195
      },
      "kind": "title",
      "text": "Pre-clinical proof of concept studies further validate use of SQore in SQ drug development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ffc46e6-8f3a-4663-816e-9d68adc817f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.67,
        "x": 0.038,
        "y": 0.058
      },
      "kind": "title",
      "text": "SQore in vivo Data Supports Safety of Caffeine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d66f281-2a4f-4a0d-9609-1db879ccf685",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}